Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0403608 (ureter)
 9,655 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Nedaplatin is a derivative of cisplatin which produced less nausea & vomiting and nephrotoxicity. In the phase I study, the MTD was 120 mg/m2 and the DLF was a bone marrow suppression. The optimal dose in a phase II study was judged to be 100 mg/m2 repeated every 4 weeks. In the phase II studies, response rates obtained were 42.2% for head & neck ca., 40.9% for small cell lung ca. (SCLC), 20.5% for non-SCLS (NSCLC), 12.5% for breast ca., 51.7% for esophageal ca., 8.3% for stomach cancer. 0 for colon ca., 38.1% for bladder ca., 14.3% for pyelo-ureter tract ca., 18.8% for prostatic ca., 80.0% for testicular tumor, 37.3% for ovarian ca., 46.3% for cervical ca. Grade 3.4 thrombocytopenia, leukopenia, anemia and nausea & vomiting were found in 28.5%, 21.1%, 16.8% and 18.5% respectively. In an additional phase II study for cervical ca. at a dose reduced to 80 mg/m2, a response rate was comparable together with less thrombocytopenia. In a randomized controlled study of nedaplatin plus vindesine vs. cisplatin plus vindesine in NSCLC, there was no significant difference in response, however mephro and G.I. toxicity were significantly less in the nedaplatin group. Thrombocytopenia was found more frequently in the nedaplatin groups. Based on the results, the indication was approved in ca. of the head & neck, SCLC, NSCLC, esophagus, bladder, testicular tumor, ovary and cervix. Dose schedule is 80 - 100 mg/m2 every 4 weeks at more 1,000 mL drip infusion repeated.
 ...
PMID:[Nedaplatin]. 871 35

The diagnosis of multiple primary malignancies (MPMs) in a patient has been reported rather frequently during the past decade. Here we present two cases with three synchronous primary malignant tumors. The first patient is a 66-year-old male with synchronous colorectal cancer, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC). The second patient is a 64-year-old female with breast cancer, transitional cell carcinoma of the ureter and endometrial cancer. MPMs seem to be diagnosed in a higher incidence than that predicted only by the influence of hazard and, whenever found, they raise questions regarding not only possible common etiologic factors or same pathogenetic mechanisms but also they cause a lot of troubles to both clinicians and patients because the therapeutic options usually become limited.
...
PMID:Multiple primary malignancies: a report of two cases. 2482 64